Zobrazeno 1 - 10
of 11
pro vyhledávání: '"BUZDAR, A"'
Autor:
Eleftherios P. Mamounas, Michael Baum, Mitchell Dowsett, Anthony Howell, Generosa Grana, Robert W. Carlson, Richard M. Elledge, William J. Gradishar, D. Craig Allred, Aman U. Buzdar
Publikováno v:
The Breast Journal. 9:213-222
This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer
Publikováno v:
Breast Cancer Research and Treatment. 58:157-162
Background. This paper reports on the clinical relevance of durable static disease (SD) (≥24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. Patients and methods. All patients were part of two prospective, randomi
Autor:
Aman U. Buzdar
Publikováno v:
Endocrine-related cancer. :219-225
A number of potent and selective non-steroidal aromatase inhibitors are now available for treatment of advanced breast cancer in postmenopausal women, of which anastrozole and letrozole, in particular, represent a significant advantage over the earli
Autor:
Aman U. Buzdar, Laura Boehnke Michaud
Publikováno v:
Drug Safety. 21:297-309
Aromatase inhibitors were first reported in the early 1970s and have been used to treat breast cancer since that time. Until recently, essentially the only agent available in this class was aminoglutethimide, a nonspecific inhibitor with multiple adv
Autor:
L D O Richard Theriault, Aman U. Buzdar, Paolo Morandi, Gabriel Hortobagyi, Roman Rouzier, Kadri Altundag
Publikováno v:
Cancer. 101(7)
BACKGROUND The authors examined the published evidence on the use of aromatase inhibitors (AIs) in the adjuvant setting in postmenopausal, hormone receptor–positive patients, and they provide recommendations for clinical management in 3 different s
Autor:
Aman U. Buzdar
Publikováno v:
Clinical breast cancer. 4
Recent advances have been made in the hormonal treatment of breast cancer with the advent of third- generation aromatase inhibitors (anastrozole, letrozole, and exemestane). These newer agents have substantial antitumor activity and appear to be as e
Autor:
Aman U. Buzdar, Michael J. Baum
Publikováno v:
The Surgical clinics of North America. 83(4)
The third generation of specific aromatase inhibitors (AIs) - anastrozole, letrozole and exemestane, which reduce the biosynthesis of estrogen-have made an exciting contribution to the management of hormone-responsive breast cancer. Their role in adv
Publikováno v:
Cancer. 95(9)
BACKGROUND The newer generation, nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole have shown superior efficacy compared with tamoxifen as first-line treatments and compared with megestrol acetate as second-line therapy in postmenopau
Autor:
Aman U. Buzdar
Publikováno v:
Breast cancer research and treatment. 75
Aromatase inhibitors (AIs) are a class of compounds that inhibit the cytochrome P450 aromatase enzyme that mediates conversion of androgens to estrogen in the adrenal gland. AIs have been approved for second-line and, more recently, first-line treatm
Autor:
Aman U. Buzdar
Publikováno v:
The Journal of steroid biochemistry and molecular biology. 79(1-5)
The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as se